The Risks of Teen Vaping: Understanding E-Cigarette Addiction

Sep.05.2022
The Risks of Teen Vaping: Understanding E-Cigarette Addiction
Electronic cigarettes are popular with teens, but can be addictive and pose health risks. CDC data shows rising use.

According to data from the CDC, electronic cigarettes have been the most commonly used tobacco products among youth since 2014. Many young people believe that using e-cigarettes or vaping is not a big deal, and as a result, the number of youth using electronic cigarettes is increasing.


The working principle of e-cigarettes involves heating a liquid until it turns into vapor, and then inhaling it. The inhaled liquid may contain oil, marijuana, or the most common ingredient, nicotine. According to a 2021 report from the CDC, one in every 35 middle school students and one in every nine high school students have used e-cigarettes in the past 30 days.


According to Child Mind Institute, addiction is easy for teenagers because their brains are still developing, making them more vulnerable to addiction. Nicotine found in electronic cigarettes can cause harm to their developing brains.


Many e-cigarette users believe that using these products is a safer alternative to traditional tobacco use and will aid in smoking cessation efforts. However, e-cigarettes and their accompanying products can lead to addiction, with some studies suggesting that they are more difficult to quit than traditional cigarettes. This is due to the increased levels of nicotine found in e-cigarettes.


There are many factors that can lead teenagers to decide to use electronic cigarettes: they may see family members or friends using them, and companies tend to design packaging to enhance the appeal of different flavors and varieties of e-cigarettes to teenagers. Additionally, e-cigarette products are cheaper and more readily available than traditional tobacco products.


Using e-cigarettes poses some health risks, including addiction, anxiety and depression, acid reflux, sleep problems, increased thirst due to mouth and throat dehydration, chronic coughing, nosebleeds, exposure to carcinogenic chemicals, chronic bronchitis, and potentially life-threatening lung injuries.


Statement: 1. This article is compiled from third-party information for the purpose of industry exchange and learning. 2. The views expressed in this article do not represent those of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The compilation of this article is intended for industry exchange and research only. 3. Due to limited compilation ability, the compiled article may not express the original text exactly the same, please refer to the original text. 4. Regarding any domestic, Hong Kong, Macao, Taiwan, and foreign statements and positions, 2FIRSTS is completely aligned with the Chinese government. 5. The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to delete it.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

AHA Journal Study: WS-23 Triples Premature Heartbeats, Raising Concerns Over Vape Cooling Agents
AHA Journal Study: WS-23 Triples Premature Heartbeats, Raising Concerns Over Vape Cooling Agents
A University of Louisville research team published a study in an American Heart Association journal suggesting that synthetic cooling agents used in e-cigarettes, including WS-3 and WS-23, may disrupt cardiac electrical activity and increase arrhythmia risk. In animal experiments, WS-23 tripled premature heartbeats.
Jun.16
Pennsylvania Updates ENDS Certification List as Chinese-Linked Manufacturers Enter State Review
Pennsylvania Updates ENDS Certification List as Chinese-Linked Manufacturers Enter State Review
Pennsylvania’s June 26 Pending ENDS Certifications list includes 23 manufacturers under review, including Shenzhen Smoore, Shenzhen IVPS, YME Technology and China-linked Boulder International. The list shows state-level vape regulation moving beyond retail brands toward manufacturer-based market access alongside FDA oversight.
Regulations
Jul.06 by 2Firsts Perspectives
French Vape Distributor Kumulus Vape Yields About 3% as Earnings Growth Stalls
French Vape Distributor Kumulus Vape Yields About 3% as Earnings Growth Stalls
Listed French vape distributor Kumulus Vape will trade ex-dividend on June 26, 2026, and pay an annual dividend of €0.10 per share on June 30, with Simply Wall St saying the payout is covered by profit and free cash flow, while weak earnings growth remains a concern.
Industry InsightMarketNews
Jun.24
UK Local Council Proposes £5 Refundable Deposit on Vape Devices
UK Local Council Proposes £5 Refundable Deposit on Vape Devices
Norwich City Council is set to debate a proposed vape deposit scheme that would require consumers to pay an extra refundable £5 per device at purchase, with the money returned when the device is handed back, as recent recycling-facility fires, including a major Widnes blaze reportedly very likely caused by a vape, draw greater attention to the risks of improperly discarded lithium-battery devices.
Jul.01
Ireland Vape Bill Passes Dáil, Setting Limits on Flavours, Packaging and Retail Display
Ireland Vape Bill Passes Dáil, Setting Limits on Flavours, Packaging and Retail Display
Ireland’s Public Health (Tobacco Products and Nicotine Inhaling Products) (Amendment) Bill 2026 has passed final stage in the Dáil and will move to the Seanad, with measures to limit vape flavours to tobacco or unflavoured products and tighten rules on packaging colours, retail advertising, in-store displays and sales of nicotine pouches to minors.
News
Jun.26 by 2Firsts Perspectives
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
CTT Pharmaceutical Holdings said it has signed a letter of intent with a U.S. company to conduct clinical trials and testing for several potential nicotine products using its patented oral thin-film technology.
Jun.18